安徽医学
安徽醫學
안휘의학
ANHUI MEDICAL JOURNAL
2014年
12期
1641-1643
,共3页
詹必成%刘建%陈剑%杜少鸣%张凡
詹必成%劉建%陳劍%杜少鳴%張凡
첨필성%류건%진검%두소명%장범
食管癌%食管切除术%胸腔镜%腹腔镜
食管癌%食管切除術%胸腔鏡%腹腔鏡
식관암%식관절제술%흉강경%복강경
Esophageal cancer%Esophagcetomy%Thoracoscopy%Laparoscopy
目的:探讨使用胸腹腔镜完成 Ivor-Lewis 食管癌根治术的可行性及近期疗效。方法我院2012年7月至2014年4月收治的60例患者行胸腹腔镜联合下 Ivor-Lewis 食管癌根治术,胸腔镜下完成食管-胃胸内吻合。结果中转开胸2例。手术时间215~400 min,术中出血30~500 mL,清扫胸部淋巴结6~18枚,腹部1~14枚。术后:肺炎7例,吻合口瘘3例,均保守治愈。1例术后10个月死于转移。结论采用胸腹腔镜行 Ivor-Lewis 食管癌根治术安全可行,近期疗效满意。
目的:探討使用胸腹腔鏡完成 Ivor-Lewis 食管癌根治術的可行性及近期療效。方法我院2012年7月至2014年4月收治的60例患者行胸腹腔鏡聯閤下 Ivor-Lewis 食管癌根治術,胸腔鏡下完成食管-胃胸內吻閤。結果中轉開胸2例。手術時間215~400 min,術中齣血30~500 mL,清掃胸部淋巴結6~18枚,腹部1~14枚。術後:肺炎7例,吻閤口瘺3例,均保守治愈。1例術後10箇月死于轉移。結論採用胸腹腔鏡行 Ivor-Lewis 食管癌根治術安全可行,近期療效滿意。
목적:탐토사용흉복강경완성 Ivor-Lewis 식관암근치술적가행성급근기료효。방법아원2012년7월지2014년4월수치적60례환자행흉복강경연합하 Ivor-Lewis 식관암근치술,흉강경하완성식관-위흉내문합。결과중전개흉2례。수술시간215~400 min,술중출혈30~500 mL,청소흉부림파결6~18매,복부1~14매。술후:폐염7례,문합구루3례,균보수치유。1례술후10개월사우전이。결론채용흉복강경행 Ivor-Lewis 식관암근치술안전가행,근기료효만의。
Objective To explore the feasibility and short -term efficacy of combined thoracoscopic and laparoscopic radical Ivor-Lewis esophagectomy for the treatment of esophageal cancer.Methods From July 2012 to April 2014,60 cases with esophageal cancer were treated by combined laparoscopic and thoracoscopic Ivor-Lewis esophagectomy.The intrathoracic esophago-gastric anastomosis was created u-sing a pursestring stapled anastomotic technique.Results Among 60 cases,2 cases were converted to thoracotomy due to dense pleural adhe-sions.The operation time was 215 ~400 min,and the intraoperative blood loss was 30 ~500 mL.The number of harvested lymph nodes from thorax was 6 ~18,and from abdomen was 1 ~14.Postoperative complications included 7 cases of pulmonary infections,3 of anastomotic fistu-las,which were cured by conservative treatment.Followed up for 1 ~12 months postoperatively,one died of metastasis after 10 months,and there was no other matastasis and death.Conclusion Combined thoracoscopic and laparoscopic Ivor-Lewis esophagectomy is a feasible and safe treatment for patients with middle or lower esophageal cancer.The short-term efficacy is satisfactory.